Solutions for MDSC Immunomodulation in TME
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides global collaborators with solutions and related services to study the relationship between tumor immunity and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME), helping them to rapidly achieve their research goals.
Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) are a population of immature, highly heterogeneous cells with potent immunosuppressive functions and are therefore considered to be one of the major factors promoting tumor development. Studies in mice and humans have shown that MDSCs accumulate in most tumor settings and promote tumor development by suppressing the antitumor immune response, MDSCs exert immunosuppressive efficacy mainly by depleting amino acids essential for T cell activation and proliferation, expressing immunosuppressive checkpoint molecules, recruiting regulatory T cells and secreting immunosuppressive factors. Understanding the biological properties of MDSCs and their immunosuppressive functions and regulatory roles in the tumor microenvironment is essential for immunotherapy targeting MDSCs, and aims to provide a more comprehensive theoretical basis for clinical immunotherapy targeting MDSCs.
Immunotherapy targeting MDSCs is currently one of the hottest research directions in the field of tumor immunotherapy. The main strategy is to reduce the number of MDSCs, weaken their immunosuppressive function, promote the differentiation of MDSCs to a non-immunosuppressive state and inhibit their recruitment and trafficking. Alfa Oncology has established a tumor microenvironment technology platform and developed several emerging technologies through which it helps global collaborators to deeply explore the relationship between tumor immunity and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME), hoping to find potential targets for tumor therapy in the process and provide new ideas for clinical anti-tumor treatment.
In recent years, with the wide application of high-throughput technologies such as gene chips and next - generation gene sequencing, more and more gene mutations have been identified in MDS patients, including:TET2, RUNX1, ASXL1, DNMT3A, EZH2, N-RAS/K-RAS, SF3B1 and so on. The discovery of these molecular abnormalities provides important molecular markers for the study of diagnosis, typing, pathogenesis and immune regulation of MDS.
Tumor progression and treatment prognosis are closely related to the tumor microenvironment on which it depends. Immune cells, as an important surveillance and defense force of the body, may play distinct roles within the tumor. Clarifying the polarization status of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment is an important guideline for studying tumor immunotherapy and predicting clinical prognosis. Alfa Oncology uses flowmetry to detect the polarization status of Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, which is one of the main methods to investigate the function and immunomodulatory role of Myeloid-derived suppressor cells (MDSCs).
Molecular level assays (sequencing, qPCR) and flow cytometric analysis are able to discriminate a sufficient number of genotypic or cellular components, but are unable to determine the spatial positional relationships of these components in tissue in situ, and such localization relationships (context) are essential to understand their role in the tissue microenvironment. Multi-marker landscape analysis is an effective tool for tumor microenvironment research (Phenotype with morphology), which involves multiple molecular markers (>7) compounded on a single tissue sample, presenting multiple information within the same screen, and together with quantitative software analysis, providing a comprehensive analysis of target molecules or cells and their associated factors in the tissue microenvironment. This technique is a superb choice for probing the function and immune regulation of MDSCs in the microenvironment.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.